Max Kozlov For many cancer survivors, the triumph of remission is undercut by a debilitating side effect: hands and feet that feel as though they are constantly burning, prickling with needles or encased in ice. Now, researchers studying this condition, called neuropathy, in mice have identified an unexpected defence against it: psilocybin, the psychoactive compound found in magic mushrooms. Just two doses of psilocybin administered before chemotherapy completely prevented mice from developing neuropathy. The condition affects as many as 60% of people treated with platinum-based cancer drugs, which are widely used to treat tumours of the ovaries and lungs, for example. The results, published today in Science, offer evidence that psilocybin could help to protect nerve fibres before chemotherapy causes lasting injury1 — which current approaches can’t effectively prevent or treat. “This study pushes the needle beyond the canonical indications of psychedelics like depression, addiction, anxiety, PTSD [post-traumatic stress disorder],” says study co-author Moran Amit, a surgical oncologist at the MD Anderson Cancer Center in Houston, Texas. “For the first time, we’re looking at pain,” he says. “And we’re actually showing a really significant efficacy not in treating that, but in preventing that.” Platinum-based cancer drugs and other chemotherapies cause neuropathy by damaging some of the information-gathering ‘sensory’ neurons that extend into the skin’s outer layers. Energy-producing organelles called mitochondria travel long distances through these neurons to the cells’ tips in the skin, but some chemotherapies can disrupt that process. Depleted of energy, the neurons’ tips degenerate, dulling tactile sensation and sparking chronic pain. © 2026 Springer Nature Limited

Keyword: Drug Abuse; Neurotoxins
Link ID: 30392 - Posted: 09.05.2026

Lynne Peeples Every year, millions of people start taking a drug with therapeutic effects that can’t be fully explained, for a condition that can’t be objectively diagnosed with a laboratory test. Selective serotonin reuptake inhibitors, or SSRIs, are among the most prescribed medications in the world. Yet, even after decades of use, scientists are still untangling the biological changes that SSRIs trigger in the brain and body. “We fundamentally don’t know how they work,” says Maurizio Fava, a psychiatrist at Massachusetts General Hospital in Boston. That uncertainty collided with politics earlier this year when, speaking at a wellness summit focused on mental health, US Secretary of Health Robert F. Kennedy Jr argued that the drugs are greatly overused and have withdrawal risks that are on a par with heroin. His claims prompted an outcry from some scientists and clinicians, who warned that Kennedy had overstated the concern, potentially scaring people away from life-saving treatment. But others said he had identified a real problem, even if clumsily. “This is a major public-health issue,” says Mark Horowitz, a psychiatrist at Adelaide University in Australia. “I hope the messenger’s controversialness doesn’t kill the message.” The divide reflects how much remains unresolved with regards to SSRIs. Researchers are still piecing together a complicated picture of the drugs’ therapeutic actions, involving neural circuits and their connecting synapses, gene expression, inflammation, stress hormones and psychological expectation. None yet offers a complete explanation. And the chain of biological changes that ultimately relieves symptoms can look very different from one person to the next. “There’s not one route to depression,” says Catherine Harmer, a cognitive neuroscientist at the University of Oxford, UK. But many scientists say the field is entering a more revealing era, as new tools begin to connect symptoms to biological processes. “We’re at an inflection point,” says Mark Rapaport, a psychiatrist at Stanford University in California and president of the American Psychiatric Association. He likens it to cancer research in the 1990s, when advances in molecular biology and basic science were leading to the development of the first targeted therapies. © 2026 Springer Nature Limited

Keyword: Depression
Link ID: 30391 - Posted: 08.29.2026

By Amanda Heidt Earlier this month, the US Food and Drug Administration approved the first drug designed to treat the root cause of narcolepsy, a condition that affects millions of people by causing extreme sleepiness during the day and wakefulness at night. The success of the drug, called oveporexton and marketed as Orzeyful, is being celebrated by those who struggle with narcolepsy. “It’s the best thing that has ever happened to me,” says Tyler Chapman, who volunteered for one of the clinical trials that contributed to the drug’s approval. But it’s also being watched with anticipation by researchers, who see it as the first in a line of therapies for sleep disorders that are likely to be approved in the coming years. These emerging treatments, known as orexin agonists, are exciting because they promise not just to alleviate symptoms of narcolepsy but also to target the disease’s biological cause — and might even have implications for other neuropsychiatric disorders. With this new strategy against narcolepsy, pharmaceutical companies have jumped at the chance to tap into a market that is projected to top US$6.4 billion annually by the early 2030s. “This is a tremendously exciting time for patients and for clinicians and scientists who have been working towards this for many years,” says Barry Lubarsky, the vice-president of medical affairs at the pharmaceutical company Alkermes, which is based in Dublin and is developing its own narcolepsy treatment. A chance to feel normal For Chapman, a 19-year-old student at the University of Tennessee, Knoxville, the milestone is life changing. Chapman had long struggled with his condition, at times sleeping for 16 hours a day, struggling in school and relying heavily on coffee. When he laughed, it would sometimes trigger his body to collapse, even though he remained fully conscious — a symptom known as cataplexy. Instead of experiencing all that university life has to offer, Chapman says that he rarely went out. © 2026 Springer Nature Limited

Keyword: Narcolepsy; Sleep
Link ID: 30379 - Posted: 08.19.2026

Emily Mullin Erin McNulty had been missing for weeks when her mother, Linda, sat down on a chair in her living room, exhausted. Linda had put in her usual seven-day workweek at the antiques shop she runs near Burlington, Vermont. She’d spent her free evenings driving around, trying to track down her daughter. Erin, 45 at the time, had been using methamphetamine for years. Her substance use started in high school—first alcohol, then marijuana, and eventually heroin. Erin’s brother used heroin, too. When Linda found out, she started driving her kids to a methadone clinic three hours away in Massachusetts. The methadone helped, but it made Erin feel tired all the time, so she started using cocaine to stay awake. There were stretches of sobriety—she had her daughter during one of them, in 2008. The family took trips to the Great Escape waterpark in New York and Hampton Beach in New Hampshire. There were also several overdoses and attempts at rehab. Eventually, Erin switched to suboxone and stopped using heroin. But when a friend introduced her to meth, Linda says, “Erin was gone.” Linda turned on the TV and was flipping through the channels when a 60 Minutes segment caught her attention. It was early 2024, and the show focused on a procedure that might help people with substance use disorders. Linda immediately thought of her daughter. The procedure involved beaming ultrasound through the skull to treat the brain. Researchers at West Virginia University were testing it on people with Alzheimer’s disease and addiction. The neurosurgeon behind the procedure, Ali Rezai, was a pioneer in the field of deep brain stimulation, which involves cutting into the skull to implant electrodes that can reach neurons deep in the brain. He was excited by the ability of ultrasound—the imaging tool best known for observing fetal development during pregnancy—to reach into the same brain structures without breaking the skin. There would be no drilling into the skull, no poking or prodding the brain’s delicate tissue. The ultrasound could be delivered in 20 minutes, and patients could go home the same day. © 2026 Condé Nast.

Keyword: Drug Abuse; Biomechanics
Link ID: 30375 - Posted: 08.15.2026

By Camille Bromley When Cameron LaBar was a kid, he was a towhead with bright blue eyes and big feelings. He seemed to sense things more strongly than other children. His family lived in Southern California, and when he was at the beach or playing in the yard, they’d put him on a double layer of towels so he wouldn’t scream when he got sand on his hands or was poked by the grass. Susan LaBar, his mother, called him the flip-top baby. He’d build up to a certain pressure, then erupt in tears. Around the age of 5, his face and body began repetitively twitching in ways he couldn’t control. Ms. LaBar bought books on Tourette’s syndrome and started highlighting things she recognized — until she was almost coloring in whole pages. In fourth grade, his teacher called her and said that he had gotten overwhelmed with instructions on an assignment and froze at his desk. She took him to a pediatric neurologist, who diagnosed him with Tourette’s syndrome, obsessive-compulsive disorder and generalized anxiety disorder. Of her five children, Ms. LaBar thought, he was the most like her: anxious and sensitive. “He can’t take a deep breath,” she told the doctor. “He’s so knotted up.” The doctor suggested that Paxil, an antidepressant in the category known as S.S.R.I.s, could level things out for him. The doctor told her that Paxil would adjust what was going on in his head so he could do what he needed to do: relax, sit down in class and complete his homework. Giving her son psychiatric medication at 9 years old was not a decision Ms. LaBar took lightly. She thought about it every night for a week, then called the doctor and asked for a prescription at the lowest dose that would help him get unstuck from inside his own head. More than 20 years later, as an adult, Mr. LaBar looks back on that moment with ambivalence and regret. It was the start of a prolonged pharmaceutical spiral that kept him on medication without egress. He believes that the years he spent on antidepressants kept him from feeling the full range of his emotions — from living a full authentic life, even. He was not alone: When he described his experience online, he encountered a multitude of others who had a similar story. © 2026 The New York Times Company

Keyword: Depression
Link ID: 30364 - Posted: 08.08.2026

By Alexandra Pattillo It was 2022, and Christina was running out of options. The Londoner, then age 34, was desperate to fix her anorexia nervosa, even as the disease consumed her. After six years of battling the disease, she’d tried various forms of behavioral therapy and months of in-patient care, but nothing stuck. At its worst, the disease was preventing her from sleeping and zapping so much energy that she was unable to climb her stairs or brush her teeth. She needed a radical fix. “You become your anorexia,” says Christina (a pseudonym to protect her privacy). “You have no life around it. You don’t laugh. You don’t smile. You don’t find joy in anything,” she recalls. Her relationships suffered, and she almost lost her job and house. Eventually, a frantic Google search for “cures for anorexia” alerted her to a clinical trial for the psychedelic psilocybin—an active ingredient in magic mushrooms—as a treatment for the disease. She signed up. “I genuinely believe, had I not done that trial, I would either be stuck in a hospital loop, or I wouldn't be here today,” she says. “It saved my life.” Life with an eating disorder can turn the mind and body into a prison. Intrusive, never-ending thought spirals drive compulsive behaviors such as binging, overexercising, purging and restrictive eating. Conventional psychiatric treatments, such as cognitive-behavioral therapy or antidepressants, work in only about half of patients. People with anorexia are more than 18 times more likely to die by suicide than the general population—the highest mortality rate of any psychiatric disorder. © 2026 SCIENTIFIC AMERICAN INC.

Keyword: Anorexia & Bulimia; Drug Abuse
Link ID: 30357 - Posted: 08.05.2026

By Kristen French Psychedelics get humans high. On this point, there is no question. For centuries, Indigenous shamans, the mystically inclined, and the neuro-curious have been ingesting the trippy stuff to incur strange visions and otherworldly flights. But why psychedelics evolved is less clear and remains the subject of strenuous debate. Tiny amounts of DMT are naturally produced in the brains of humans and other mammals, which has led some neuroscientists and ethnobotanists to argue that hallucination may have some direct evolutionary or therapeutic benefit to humans, that the DMT is there to serve a special visionary or consciousness-related function, and that psychedelic plants may have co-evolved for human spiritual use. But the authors of a new study published in Proceedings of the National Academy of Sciences argue that human hallucination is more likely just a side effect, and that psychedelics probably evolved as ecological tools, allowing various animals and plants to defend against predators and herbivores or to help manage symbiotic relationships. After all, hallucinogens like psilocybin, mescaline, and DMT are extremely common in the animal kingdom, appearing independently in numerous unrelated organisms such as mushrooms, cacti, toads, and sponges. “Understanding why evolution produced these molecules doesn’t diminish their therapeutic value,” wrote study author Yibo Wang, a chemist at the Chinese Academy of Sciences, in an email. “Instead, it provides a deeper biological framework for discovering better medicines while promoting conservation and sustainable production.” Wang and his team propose that humans hallucinate when we ingest psychedelics because we share ancient brain chemistry with the creatures who were the original targets of the compounds, such as slugs, insects, and sea urchins. The receptors these compounds mess with—serotonin, opioid, and GABA receptors—are also found all over the animal kingdom. So the chemicals that scramble human perception may also deter snails from eating certain plants, the researchers suggest. © Copyright 2026

Keyword: Drug Abuse
Link ID: 30343 - Posted: 07.25.2026

Lynne Peeples Every heartbeat is choreographed not just by the brain but also by a mysterious nervous system embedded in the heart itself. Now, scientists studying mice have started to unravel how this complex system works to keep the heart beating steadily even at times of extreme stress — findings that challenge the classic view that all cardiac neurons are alike. “The key is to keep the heart functional no matter what happens. Because if the pump function stops, you will die,” says Rui Chang, a neuroscientist at Yale University School of Medicine in New Haven, Connecticut, and co-author of the new paper. The findings, published today in Cell1, could inform better treatments for heart disease. Like the gut’s widely recognized ‘second brain’, the heart contains a mini-brain of its own — known, more formally, as the intrinsic cardiac nervous system. This network of neurons is embedded in the fat pad surrounding the heart. The system’s neurons exchange messages with the brain and with each other, and are the final players in a long chain of neurons that controls cardiac function. But because intrinsic cardiac neurons are exceedingly rare, making up only about 0.01% of the cells in a piece of heart tissue, their precise roles have been hard to pin down, says Chang. Damage from a heart attack comes from brain signals, mouse study suggests To fill that gap, his team genetically engineered mice to label all of the animals’ cardiac neurons. The scientists sequenced genes isolated from these neurons and identified markers for two neuronal subtypes. They then used techniques such as high-resolution imaging to identify the genetically distinct subtypes’ core functions and to map their locations. © 2026 Springer Nature Limited

Keyword: Emotions
Link ID: 30336 - Posted: 07.22.2026

Christina Jewett The ads were jarring: a man with a hole in his throat where his larynx, or voice box, had once been. A woman whose teeth and jaw had been removed after oral cancer. Another woman speaking in a robotic voice, which was altered when her larynx was removed: “I wish I’d never seen a cigarette in my entire life.” A black screen followed, saying she died two days later. The Centers for Disease Control and Prevention’s 14-year ad campaign, called Tips From Former Smokers, was highly memorable and, research shows, highly effective in motivating people to quit. Last year, though, as tobacco companies gave millions to political organizations related to the Trump administration, the campaign went dark. There is no definitive evidence linking the donations to the lapse of the ad campaign. But the decision to terminate it was one of several steps the administration has taken to unravel federal government antismoking initiatives that had long had bipartisan support during a time when the administration has delivered significant policy wins to tobacco companies. The C.D.C.’s Office on Smoking and Health, which managed the campaign and worked with states on smoking cessation measures, has been shut down for more than a year, after its staff was laid off as part of the administration’s government downsizing efforts. While hundreds of other federal health employees were eventually rehired, the smoking office staff members have not been. Even after Congress restored the office’s funding late last summer, its employees have remained on paid leave as litigation challenging the firings plays out. In recent weeks, under pressure from Congress, the C.D.C. has given states diminished funding to air ads from the campaign’s archive, but the federal government will not produce new ads or negotiate contracts for them to air nationwide. The ads had prompted millions of smokers to dial state quit lines for help on how to stop smoking. In interviews, people who ran quit lines in several states said that since the ads went off the air, calls have plummeted along with enrollment in programs that offered counseling and nicotine gum and patches. © 2026 The New York Times Company

Keyword: Drug Abuse
Link ID: 30311 - Posted: 07.08.2026

By Simon Makin A new tool makes it possible to probe brain circuit function without the kind of external stimulation required in optogenetics and chemogenetics. The method uses engineered electrical synapses to edit brain circuits. These designer synapses function in living mice, altering activity in cells, circuits and networks, with corresponding effects on behavior. In contrast to tools that involve external stimulation, the result is autonomous. “Here, all the information is completely natural; it’s only how the brain manipulates this information that’s being altered,” says Ithai Rabinowitch, assistant professor of neurobiology at the Hebrew University of Jerusalem, who was not involved in the work. “This is really important, in my view.” The technique, called LinCx (long-term integration of circuits using connexins) could be used to investigate relationships between circuit structure and function, as well as the duties of natural electrical synapses. “It’s potentially a useful tool if it’s used intelligently and thoughtfully to ask questions about the role of electrical synapses in brain circuits,” says Eve Marder, professor of biology at Brandeis University, who was not involved in the study. Electrical synapses consist of gap junctions that, in vertebrates, are composed of connexin proteins, of which there are 21 isoforms in humans. These proteins sit in the membranes of touching cells, docked together to create channels that ions pass through, coupling the cells’ activity. Gap junctions in invertebrates are composed of innexins, which don’t interact with connexins, so expressing a mammalian connexin in Caenorhabditis elegans enabled researchers to rewire an olfactory circuit and flip the worms’ behavior from odor attraction to avoidance, according to a 2014 study. © 2026 Simons Foundation

Keyword: Drug Abuse; Brain imaging
Link ID: 30293 - Posted: 06.24.2026

By Kenneth P. Vogel and Christina Jewett For years, federal health officials have warned about the risks associated with a supplement derived from the leaves of kratom trees that adherents say can kill pain or boost energy. Sold in gas stations across America, kratom has been linked to liver toxicity, seizures and thousands of deaths. Powerful figures close to President Trump, including Homeland Security Secretary Markwayne Mullin, pushed to downplay those concerns. Mr. Mullin, until recently a Republican senator from Oklahoma, played a key role in a sprawling influence campaign spearheaded by the kratom industry that courted Health Secretary Robert F. Kennedy Jr. and Vice President JD Vance, among others in the Trump administration, an investigation by The New York Times found. Only when he was nominated by Mr. Trump in March to lead the Homeland Security Department did it become clear that Mr. Mullin had a financial connection to the supplement. In a disclosure statement, he listed an investment worth as much as $1 million in a kratom company, Botanic Tonics, that could benefit from the changes he has sought. The company’s founder, Jerry W. Ross — who had been an energy executive in Mr. Mullin’s home state before pleading guilty to a financial crime — is a leading player in the influence campaign that was devised to benefit kratom at the expense of its rivals in the marketplace. The kratom campaign underscores how corporations in the growing wellness industry can gain traction in Mr. Trump’s government by casting risky products as aligned with the administration’s Make America Healthy Again, or MAHA, agenda championed by Mr. Kennedy, who has sometimes prioritized unproven remedies over science. In July, while still a senator, Mr. Mullin showed up at a Food and Drug Administration news conference and endorsed proposed federal restrictions on more powerful synthetic supplements that compete with kratom for shelf space. In explaining his position, Mr. Mullin pointed to a history of addiction in his family, though health experts say kratom products have also been shown to be addictive. © 2026 The New York Times Company

Keyword: Drug Abuse
Link ID: 30281 - Posted: 06.17.2026

By Ellen Barry Most years, when thousands of psychiatrists gather for the annual meeting of the American Psychiatric Association, they walk past a scattering of protesters. There are Scientologists with megaphones; Falun Gong groups doing their exercises; and, often, former patients, saying they have been harmed by medications or electroconvulsive therapy. This year, though, the profession is facing criticism from the highest levels of the federal government. The American Psychiatric Association gathered just 10 days after Health Secretary Robert F. Kennedy Jr. announced a set of policies to encourage doctors to deprescribe, or assist patients in stopping, the most widely prescribed class of antidepressants. A current of anxiety ran through the meeting, held here this week. Many physicians in the crowd said they worried that Mr. Kennedy’s statements would prompt people to refuse medications, or to quit them and relapse. The plenary session erupted in applause when Dr. Marketa Wills, the organization’s chief executive, declared, “We will never support governmental interference in the practice of medicine.” “We are standing tall for evidence-based care,” she continued. “We are standing tall against stigma, oversimplification, and anything that would move patients further away from the care that they need.” But there were also signs that the field’s leaders are engaging, albeit cautiously, with Mr. Kennedy’s effort to curb overprescribing. Numerous sessions offered training in helping patients taper off medications. In July, the association’s president will take part in a panel convened by the Department of Health and Human Services to develop clinical guidance on tapering antidepressants. In an interview, Dr. Wills said she had been “encouraged” by the invitation to participate in the panel, and she credited the administration with “putting mental health front and center.” © 2026 The New York Times Company

Keyword: Depression
Link ID: 30256 - Posted: 05.27.2026

By Matt Richtel A 27-year-old woman began an experiment on herself early one morning in December 2024. Her laboratory was her childhood bedroom, tucked into a second-floor corner of a pale yellow house in the Boston suburbs. On a bookshelf behind her sat a small stuffed sloth and some favorite books, including “Siddhartha” by Hermann Hesse. Her parents were asleep in the room next door. Her name is Rebecca, but she goes by Becks. Sitting at her desk in a gray T-shirt, she opened a small plastic bag filled with white powder. The bag was stamped “SR-17018,” and “NOT FOR HUMAN CONSUMPTION.” She extracted some powder with a red microscooper, poured it onto a digital scale and carefully weighed out 25 milligrams. She gathered this into a blue and white pill capsule and sealed it, and then swallowed the capsule with water. It was 4:27 a.m. “It’s my turn to be a guinea pig,” Becks wrote in the online diary she was keeping of her experience. In sharing her story with The New York Times, she asked that her last name not be used so potential employers don’t discover her drug history. Becks had joined the vanguard of a dangerous, highly speculative do-it-yourself approach to getting sober. For a decade, on and off, she had been addicted to various drugs, most recently kratom, an opiate-like substance, which cleared her head and covered up her pain but required constant dosing. She feared the call of fentanyl, which she’d tried a few times. “Every morning, I woke drenched in sweat from overnight withdrawals. It was a grim existence,” she wrote of her kratom use. She tried various methods to get sober, including three short inpatient detox stays and one monthlong rehabilitation treatment. She had periods of sobriety but couldn’t sustain it. © 2026 The New York Times Company

Keyword: Drug Abuse; Depression
Link ID: 30241 - Posted: 05.09.2026

By Rachel Nuwer Despite billions of dollars spent on potential drug treatments for cocaine addiction, none have proved effective—and cocaine use is increasing in the United States and around the world. But one class of possible remedy has remained untested: psychedelics, which have shown promise for treating post-traumatic stress disorder, depression, anxiety, alcohol use disorder, smoking, and more. Now, the results of a pioneering randomized trial—more than a decade in the making—reveal a single dose of psilocybin, the psychedelic component of magic mushrooms, brought significant relief for people addicted to cocaine. The study of 40 people, described today in JAMA Network Open, showed that 180 days after treatment, 30% of the psilocybin group was completely abstaining from cocaine, versus none of the placebo group—and those who continued using the drug did so less frequently. “This is significantly better than any medication ever tested to treat cocaine use disorder,” says Stephen Ross, a professor of psychiatry at New York University who was not involved in the work. He called results “remarkable,” and the magnitude of the effects “highly substantial.” The study, funded by the University of Alabama at Birmingham (UAB) and the nonprofit Heffter Research Institute, was also notable for its participant pool. Of the 40 people who took part, more than 80% were Black and 65% earned less than $20,000 a year. “Although the study was small, one strength is that most participants had lower than average income and education, which are associated with barriers to addiction treatment,” says Nora Volkow, director of the National Institute on Drug Abuse, who was not involved in the trial. More research will be needed to replicate the findings, she says, but the study provides evidence “that psilocybin has promise for treating addiction to cocaine and potentially other illicit stimulants.” © 2026 American Association for the Advancement of Science.

Keyword: Drug Abuse
Link ID: 30240 - Posted: 05.09.2026

Ian Sample Science editor A single dose of psilocybin, the active ingredient in magic mushrooms, can induce anatomical changes in the brain, according to research among people who took the psychedelic compound for the first time. Scientists spotted apparent changes in the brain’s structure which were still apparent a month after healthy volunteers took the drug. If confirmed, they may help explain the therapeutic effects that psychedelics can have on anxiety, depression and addiction, researchers said. Evidence for the changes came from specialised scans that measured the diffusion of water along nerve bundles in the brain. They suggested that some nerve tracts had become denser and more robust after the drug was taken. While the findings are preliminary, the scientists said the opposite was seen in ageing and dementia. “It’s remarkable to see potential anatomical brain changes one month after a single dose of any drug,” said Prof Robin Carhart-Harris, a neurologist at the University of California, San Francisco, and senior author on the study. “We don’t yet know what these changes mean, but we do note that overall, people showed positive psychological changes in this study, including improved wellbeing and mental flexibility.” Scientists have long sought to understand how psychedelics affect the brain and the work has gained fresh impetus in the wake of trials and studies that suggest the compounds could be used to treat a range of mental health disorders. The drugs are thought to help by boosting flexible thinking and allowing people to escape destructive cognitive ruts. © 2026 Guardian News & Media Limited

Keyword: Depression; Brain imaging
Link ID: 30237 - Posted: 05.06.2026

By Jake Currie Psychedelics are getting a renewed boost of interest lately. The FDA recently announced they were fast-tracking research investigating psilocybin, the compound that gives magic mushrooms their magic, as a treatment for depression. Now, new research published in Nature Communications is showing just how powerful a single dose of this psychedelic compound can be. Neuropsychopharmacologists from the University of California, San Francisco recruited 28 physically and mentally healthy people who had never taken psychedelics before and gave them their inaugural magic mushroom trip. But first, they administered a single placebo dose of 1 milligram of the magic mushroom compound. Most of the subjects reported the experience was “no more unusual than an everyday state of consciousness,” which was backed up by EEG readings. After the preview, it was time for the main event. The research team fitted the participants with EEG electrodes and administered a 25-milligram dose of psilocybin. An hour into their trip, the EEGs showed a surge of entropy (or diverse neural activity), indicating they were processing more complex information. The next day all of the subjects (except one) rated the experience as the “single most unusual state of consciousness” they’d experienced in their lives (the lone holdout rated it in the top five). During the following few weeks, the newly minted psychonauts reported experiencing more insight as well as an increased sense of well-being. A full month after their first trip, they performed better on assessments of their cognitive flexibility. “Psilocybin seems to loosen up stereotyped patterns of brain activity and give people the ability to revise entrenched patterns of thought,” study author Taylor Lyons said in a statement. “The fact that these changes track with insight and improved well‑being is especially exciting.” © 2026 Nautilus

Keyword: Drug Abuse; Depression
Link ID: 30236 - Posted: 05.06.2026

By Jan Hoffman Since last fall, new and deadly synthetic opioids called orphines have begun appearing in street drugs in the United States. They are far more potent than fentanyl but cannot be detected by standard toxicology tests. Orphines are still much less common than fentanyl, but they are proliferating quickly. As of last month, they have been found in 14 states, mostly in the South and the Midwest. Law enforcement officials and public health officials are trying to assess the gravity and endurance of the threat they pose. Here are answers to some basic questions. What are orphines? They are a class of opioids that was created in the 1960s by Paul Janssen, a Belgian doctor and pharmacologist, whose teams investigated rapid, safe pain relievers for surgery. As part of that effort, they also developed fentanyl. Dr. Janssen and others discovered that orphines had life-threatening side effects such as acute respiratory depression and were highly addictive. Within a few years, the research on them was halted. Researchers characterize orphines as 10 times more powerful than fentanyl, even in quantities no greater than a few sand-size grains. They can be lethal with stunning speed, with victims slumping over abruptly, respiration shutting down, chest walls rigid. Sometimes the classic signature of overdose, “the foam cone” — froth from the nostrils and mouth — does not even have time to bubble up. Still, it is possible for people overdosing on orphines to be revived with naloxone, the opioid reversal medication. But numerous doses may be required, many more than the one or two doses typically needed for fentanyl. © 2026 The New York Times Company

Keyword: Drug Abuse
Link ID: 30234 - Posted: 05.06.2026

By Ellen Barry As Health Secretary Robert F. Kennedy Jr. sets out to rein in the use of psychiatric medications, a group of prominent psychiatrists are developing guidance for helping patients to stop taking them, noting that providers sometimes “park” patients on medications that are no longer necessary or effective. The experts, whose first recommendations appeared in JAMA Network Open and the British Journal of Psychiatry, identify structural problems that may lead to overprescribing: There are few clinical trials showing when it is advisable to stop a medication; many providers do not regularly review whether a prescription is still needed; and psychiatry residents receive more training in starting drug prescriptions than stopping them. “We have not really taught our trainees to think about, what is the logical endpoint?” said Dr. Joseph F. Goldberg, a past president of the American Society of Clinical Psychopharmacology, which convened a group of 45 psychiatrists to agree on basic principles for “deprescribing,” as supervised drug tapering is sometimes called. “You’ll see a patient in consultation who has been parked on a medication which seems to be ineffective for years, and you’ll ask, ‘Why are you still on this medicine?’” he said. “We’ve got a bugaboo going about passive re-prescribing, and I hope we’ll see much less of that.” The new recommendations come amid rising pressure from Mr. Kennedy and his allies in the Make America Healthy Again movement, who have long made the case that Americans overuse psychiatric medications. The Department of Health and Human Services will convene expert panels on deprescribing the main class of medication used to treat depression — selective serotonin reuptake inhibitors, or S.S.R.I.s — this summer, with an eye toward developing official guidance. © 2026 The New York Times Company

Keyword: Depression
Link ID: 30228 - Posted: 05.02.2026

By Emma Yasinski “Relapse is a part of recovery”: That’s a common refrain among professionals who treat substance use disorders. Many people who have completed treatment programs return to substance use and reenter treatment multiple times, after days, weeks or even years of sobriety. Marina Wolf, a behavioral neuroscientist at the Oregon Health & Science University, studies how cells in the brain respond to drug exposure in ways that can lead people to develop powerful cravings even months after they stop using drugs such as cocaine, opioids or alcohol. Specifically, she has focused on an aspect of this problem called cue-induced craving, in which people’s brains come to associate a cue — such as seeing a certain location where they previously used drugs — with the desire to use that drug. These learned associations, as she described in the 2025 Annual Review of Pharmacology and Toxicology, are caused by structural changes to the brain — neuroplasticity — as a result of drug use, including the strengthening of connections, called synapses, between specific nerve cells. These changes don’t disappear as soon as a person, or animal, stops using a drug. Cravings, in fact, can strengthen after abstinence, leaving a person vulnerable to resume using. How did you become interested in neuroplasticity and addiction? I never had any formal training in synaptic plasticity or addiction. As a graduate student and then a postdoctoral fellow, I worked on how neurons are regulated by the neurotransmitter dopamine, but we studied dopamine’s role in antipsychotic drug effects, not addiction. But when I was setting up my own lab in the early 1990s, I had a friend from graduate school who was involved in groundbreaking studies to work out synaptic plasticity mechanisms in the brain’s hippocampus, a region of the brain responsible for encoding memories. This was fascinating work that helped demonstrate a critical role for a neurotransmitter called glutamate in synaptic plasticity, so I followed it closely. © 2026 Annual Reviews

Keyword: Drug Abuse
Link ID: 30222 - Posted: 04.29.2026

By Calli McMurray Last Saturday, President Donald Trump issued an executive order outlining regulatory tweaks intended to “accelerate” U.S. research on and increase access to psychedelic drugs for mental health treatments. The measures target clinical research, not basic studies on how the drugs work. “This may not be the breakthrough the basic research community has been looking for,” says Shawn Lockery, professor of neuroscience at the University of Oregon. The order directs the U.S. Food and Drug Administration (FDA) to speed up review of psychedelic drugs and allots “at least $50 million” from the Department of Health and Human Services for state governments’ own psychedelics research programs. One section of the order, however, could eventually make it easier for basic researchers to access psychedelics for their work. The U.S. Drug Enforcement Agency (DEA) classifies most psychedelics—including psilocybin, MDMA and LSD—as Schedule I, meaning they have “no currently accepted medical use and a high potential for abuse.” Trump’s order calls for the U.S. attorney general to review “any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder” and consider it for rescheduling to the less restrictive Schedule III. To study a Schedule I drug, researchers must apply for a license and, if approved, follow strict storage and security requirements. Approval can take up to a year, says Alex Kwan, professor of biomedical engineering at Cornell University, who studies psilocybin’s mechanism of action in the brain. “It’s a decent bar to get it. It’s not easy.” © 2026 Simons Foundation

Keyword: Drug Abuse; Depression
Link ID: 30217 - Posted: 04.26.2026